NCT03645317: ACCOLADE

Avoiding Cardiac Toxicity in Lung Cancer Patients Treated With Curative-intent Radiotherapy

Status unknown NA Last updated 2 August 2021

What this trial tests

NA trial testing Blood tests & cardiac imaging in Lung Cancer in 200 participants. Status unknown.

Timeline

12 June 2019

Primary endpoint
1 April 2022

1 July 2022

Quick facts

Lead sponsor	Prof Corinne Faivre-Finn
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	200
Start date	12 June 2019
Primary completion	1 April 2022
Estimated completion	1 July 2022
Sites	2 locations across United Kingdom

Drugs / interventions tested

• Blood tests & cardiac imaging

Conditions studied

• Lung Cancer — all drugs for Lung Cancer →

Sponsor

Prof Corinne Faivre-Finn

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Radiotherapy plays a major role in the treatment of lung cancer and recent advances in radiotherapy have led to better cure rates. However, the radiotherapy dose needed to destroy the cancer cells can unfortunately also damage the surrounding organs, such as the heart. The precise mechanism of damage and which areas of the heart are more sensitive to radiation is not currently known. This project uses the analysis of large amounts of existing radiotherapy treatment data to determine this. Establishing detailed radiotherapy dose limits for the heart and the heart's sub-structures will lead to the delivery of heart-sparing radiotherapy, where possible, in lung cancer patients treated in Yorkshire and Greater Manchester. The investigators estimate that this should lead to an improvement in one-year survival of approximately 10%.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions.
   Banfill K, Giuliani M, Aznar M, Franks K, et al · · 2021 · cited 190× · PMID 33278607 · DOI 10.1016/j.jtho.2020.11.002
2. Cell Trafficking at the Intersection of the Tumor-Immune Compartments.
   Du W, Nair P, Johnston A, Wu PH, et al · · 2022 · cited 31× · PMID 35385679 · DOI 10.1146/annurev-bioeng-110320-110749
3. Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer: An NI-HEART Analysis.
   Walls GM, Hill N, McMahon M, Kearney BÓ, et al · · 2024 · cited 11× · PMID 39239328 · DOI 10.1016/j.jaccao.2024.05.009
4. Brief Report of a New Anatomical Region at Risk in Thoracic Radiotherapy: From Discovery to Implementation.
   Banfill K, Marchant T, McWilliam A, Wood J, et al · · 2024 · cited 2× · PMID 39624251 · DOI 10.1016/j.jtocrr.2024.100742